clinical trial · NCT07639684
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D)Obesity (BMI>30)ESG with OverStitch
brief summary
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and inadequately controlled Type 2 Diabetes (T2D) despite guideline-directed therapy, including Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA)-based agents.
started
Apr 1, 2027
primary completion
Jul 1, 2029
completion
Jul 1, 2029
last updated
Sep 24, 2026
official title
Metabolic Effects of Endoscopic Sleeve Gastroplasty in Obese Adults With Type 2 Diabetes: Evaluation of Glycemic Control, Insulin Use and Obesity Response
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol